Cargando…

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer

Oncolytic viruses, including the oncolytic rhabdovirus VSV‐GP tested here, selectively infect and kill cancer cells and are a promising new therapeutic modality. Our aim was to study the efficacy of VSV‐GP, a vesicular stomatitis virus carrying the glycoprotein of lymphocytic choriomeningitis virus,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urbiola, Carles, Santer, Frédéric R., Petersson, Monika, van der Pluijm, Gabri, Horninger, Wolfgang, Erlmann, Patrik, Wollmann, Guido, Kimpel, Janine, Culig, Zoran, von Laer, Dorothee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712949/ https://www.ncbi.nlm.nih.gov/pubmed/29696636 http://dx.doi.org/10.1002/ijc.31556

Ejemplares similares

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
por: Schreiber, Liesa-Marie, et al.
Publicado: (2019)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
por: Tober, R, et al.
Publicado: (2012)

The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion
por: Heilmann, Emmanuel, et al.
Publicado: (2019)

Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP
por: Gautam, Saurabh, et al.
Publicado: (2022)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma
por: Wilkinson, Michelle J., et al.
Publicado: (2016)

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
por: Koske, Iris, et al.
Publicado: (2019)

Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP
por: Vijver, Saskia V., et al.
Publicado: (2023)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
por: Arulanandam, Rozanne, et al.
Publicado: (2020)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV
por: Yarde, Danielle N., et al.
Publicado: (2013)

Genetic Relatedness of Dolphin Rhabdovirus with Fish Rhabdoviruses
por: Siegers, Jurre Y., et al.
Publicado: (2014)

Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes
por: Naumenko, Victor, et al.
Publicado: (2022)

Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
por: Das, Krishna, et al.
Publicado: (2021)

Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy
por: Tzelepis, Fanny, et al.
Publicado: (2020)

Chemogenetic ON and OFF switches for RNA virus replication
por: Heilmann, E., et al.
Publicado: (2021)

Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review
por: Moglan, Abdulaziz Molham, et al.
Publicado: (2023)

Construction of VSVΔ51M oncolytic virus expressing human interleukin-12
por: Abdulal, Rwaa H., et al.
Publicado: (2023)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

Use of thermo‐coagulation as an alternative treatment modality in a ‘screen‐and‐treat’ programme of cervical screening in rural Malawi
por: Campbell, Christine, et al.
Publicado: (2016)

Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
por: Pan, Zhenyu, et al.
Publicado: (2016)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women
por: Gultekin, Murat, et al.
Publicado: (2017)

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100
por: De Santo, Carmela, et al.
Publicado: (2017)

Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study
por: Sun, Zimin, et al.
Publicado: (2018)

Near‐infrared photoimmunotherapy targeting EGFR—Shedding new light on glioblastoma treatment
por: Burley, Thomas A., et al.
Publicado: (2018)

Bepridil exhibits anti‐leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia
por: Baldoni, Stefano, et al.
Publicado: (2018)

The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model
por: Papaevangelou, Efthymia, et al.
Publicado: (2018)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

Cervical cancer risk in HPV‐positive women after a negative FAM19A4/mir124‐2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow‐up
por: De Strooper, Lise M.A., et al.
Publicado: (2018)

Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model
por: Qu, Sifeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m1qbdcroqk1qdif415p7d313cg